These studies should be in particular feasible, as the yet approved anti-IL23 antibody therapies for autoimmune diseases showed a favorable risk profile in terms of safety of use, especially with regard to more severe infections or malignancies (75, 78–80). Here, IL37 is linked to autoimmune disease.